Compounds > n-ethyl-1-phenylcyclohexylamine
Page last updated: 2024-11-05

n-ethyl-1-phenylcyclohexylamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-ethyl-1-phenylcyclohexylamine: RN given refers to parent cpd; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID16622
CHEMBL ID279924
SCHEMBL ID66697
MeSH IDM0081551

Synonyms (39)

Synonym
cyclohexanamine, n-ethyl-1-phenyl-
2201-15-2
wln: l6tj am2 ar
cyclohexamine
nsc231651
cyclohexylamine, n-ethyl-1-phenyl-
nsc-231651
eticyclidine
nsc 231651
n-ethyl-1-phenylcyclohexanamine
ci 400
n-ethyl-1-phenylcyclohexylamine
eticyclidine [inn]
(1-phenylcyclohexyl)ethylamine
eticyclidinum [inn-latin]
eticyclidina [spanish]
eticiclidina [inn-spanish]
ethylphencyclidine
dea no. 7455
brn 2693343
n-(1-phenylcyclohexyl)ethylamine
eticyclidinum [latin]
CHEMBL279924 ,
n-ethyl-1-phenylcyclohexan-1-amine
bdbm50028055
ethyl-(1-phenyl-cyclohexyl)-amine
o8i1ll6a89 ,
4-12-00-02968 (beilstein handbook reference)
eticyclidina
hsdb 7635
eticyclidinum
unii-o8i1ll6a89
eticiclidina
eticyclidine [incb green list]
eticyclidine [hsdb]
SCHEMBL66697
DTXSID2062248
cyclohexanamine, 1-phenyl, n-ethyl
Q2365803

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Dose-response curves and median effective doses were determined for phencyclidine, N-ethyl-1-phenylcyclohexylamine, 1-(1-(2-thienyl) cyclohexyl) piperidine and ketamine."( Comparison of phencyclidine and three analogues on fixed-interval performance in rhesus monkeys.
Balster, RL; Brady, KT; Meltzer, LT; Schwertz, D, 1980)		0.49
" Consequently, the major goal of these studies was to determine whether a monoclonal antibody Fab fragment (of IgG) could be used as an effective drug class-selective antagonist and to understand better the dose-response relationships for reversing CNS drug toxicity."( Pharmacodynamics of a monoclonal antiphencyclidine Fab with broad selectivity for phencyclidine-like drugs.
Hardin, JS; Owens, SM; Proksch, JW; Wessinger, WD, 1998)		0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
CholinesteraseMus musculus (house mouse)Ki57.77200.52000.52240.5248AID44425; AID44436
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (11)

Assay IDTitleYearJournalArticle
AID15014C(f=2) is the concentration at which the half life (t1/2) in the time course of inhibition of BChE by DFP increased by twofold in the presence of compound1984Journal of medicinal chemistry, Oct, Volume: 27, Issue:10
N-allyl analogues of phencyclidine: chemical synthesis and pharmacological properties.
AID19095Half life at a concentration 4*10e-6 M1984Journal of medicinal chemistry, Oct, Volume: 27, Issue:10
N-allyl analogues of phencyclidine: chemical synthesis and pharmacological properties.
AID19092Half life at a concentration 0 M1984Journal of medicinal chemistry, Oct, Volume: 27, Issue:10
N-allyl analogues of phencyclidine: chemical synthesis and pharmacological properties.
AID232186Ratio of half life (protection) to the control was reported at a concentration 0 M1984Journal of medicinal chemistry, Oct, Volume: 27, Issue:10
N-allyl analogues of phencyclidine: chemical synthesis and pharmacological properties.
AID19096Half life at a concentration 4*10e-7 M1984Journal of medicinal chemistry, Oct, Volume: 27, Issue:10
N-allyl analogues of phencyclidine: chemical synthesis and pharmacological properties.
AID232191Ratio of half life (protection) to the control was reported at a concentration 4*10e-7 M1984Journal of medicinal chemistry, Oct, Volume: 27, Issue:10
N-allyl analogues of phencyclidine: chemical synthesis and pharmacological properties.
AID232192Ratio of half life (protection) to the control was reported at a concentration 8*10e-6 M1984Journal of medicinal chemistry, Oct, Volume: 27, Issue:10
N-allyl analogues of phencyclidine: chemical synthesis and pharmacological properties.
AID44425-Log (Ki) value for butyrylcholinesterase by inhibiting DFP1984Journal of medicinal chemistry, Oct, Volume: 27, Issue:10
N-allyl analogues of phencyclidine: chemical synthesis and pharmacological properties.
AID232190Ratio of half life (protection) to the control was reported at a concentration 4*10e-6 M1984Journal of medicinal chemistry, Oct, Volume: 27, Issue:10
N-allyl analogues of phencyclidine: chemical synthesis and pharmacological properties.
AID19097Half life at a concentration 8*10e-6 M1984Journal of medicinal chemistry, Oct, Volume: 27, Issue:10
N-allyl analogues of phencyclidine: chemical synthesis and pharmacological properties.
AID44436Compound was evaluated for the protection of butyrylcholinesterase against DFT in mice and expressed as Ki.1984Journal of medicinal chemistry, Oct, Volume: 27, Issue:10
N-allyl analogues of phencyclidine: chemical synthesis and pharmacological properties.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (66.67)18.7374
1990's2 (33.33)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.34

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.34 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.34)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
3-methylcholanthrene
Methylcholanthrene: A carcinogen that is often used in experimental cancer studies.. 3-methylcholanthrene : A pentacyclic ortho- and peri-fused polycyclic arene consisting of a dihydrocyclopenta[ij]tetraphene ring system with a methyl substituent at the 3-position.		1.9610ortho- and peri-fused polycyclic arenearyl hydrocarbon receptor agonist;
carcinogenic agent
ketamine
Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.. ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.		1.9510cyclohexanones;
monochlorobenzenes;
secondary amino compound		analgesic;
environmental contaminant;
intravenous anaesthetic;
neurotoxin;
NMDA receptor antagonist;
xenobiotic
phencyclidine
Phencyclidine: A hallucinogen formerly used as a veterinary anesthetic, and briefly as a general anesthetic for humans. Phencyclidine is similar to KETAMINE in structure and in many of its effects. Like ketamine, it can produce a dissociative state. It exerts its pharmacological action through inhibition of NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE). As a drug of abuse, it is known as PCP and Angel Dust.. phencyclidine : A member of the class of piperidines that is piperidine in which the nitrogen is substituted with a 1-phenylcyclohexyl group. Formerly used as an anaesthetic agent, it exhibits both hallucinogenic and neurotoxic effects.		3.0750benzenes;
piperidines		anaesthetic;
neurotoxin;
NMDA receptor antagonist;
psychotropic drug
methamphetamine
Methamphetamine: A central nervous system stimulant and sympathomimetic with actions and uses similar to DEXTROAMPHETAMINE. The smokable form is a drug of abuse and is referred to as crank, crystal, crystal meth, ice, and speed.. methamphetamine : A member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent.		1.9910amphetamines;
secondary amine		central nervous system stimulant;
environmental contaminant;
neurotoxin;
psychotropic drug;
xenobiotic
deuterium
Deuterium: The stable isotope of hydrogen. It has one neutron and one proton in the nucleus.		1.9710dihydrogen
tenocyclidine
tenocyclidine : A tertiary amino compound that consists of cyclohexane having piperidin-1-yl and thiophen-2-yl groups attached at position 1. A dissociative anaesthetic drug with halluccinogenic and stimulant effects. Its effects are similar to those of phencyclidine (PCP, an analogue with the thienyl group replaced by phenyl), but it is rather more potent.		2.3820piperidines;
tertiary amino compound;
thiophenes		central nervous system stimulant;
hallucinogen;
neuroprotective agent;
NMDA receptor antagonist
ConditionIndicatedRelationship StrengthStudiesTrials
Muscle Contraction
A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.		01.9610
Ataxia
Impairment of the ability to perform smoothly coordinated voluntary movements. This condition may affect the limbs, trunk, eyes, pharynx, larynx, and other structures. Ataxia may result from impaired sensory or motor function. Sensory ataxia may result from posterior column injury or PERIPHERAL NERVE DISEASES. Motor ataxia may be associated with CEREBELLAR DISEASES; CEREBRAL CORTEX diseases; THALAMIC DISEASES; BASAL GANGLIA DISEASES; injury to the RED NUCLEUS; and other conditions.		01.9810